The antibody 7E11 binds to the intracellular epitope of PSMA and can reach this only when the cell membrane is damaged. In this case, the tumor on the right was irradiated; the left one was not. The ...

Pluvicto™ (formerly 177Lu-PSMA-617) is a radioligand therapy that was approved by the FDA in March 2022 to treat progressive, PSMA positive metastatic castration-resistant prostate cancer. Pluvicto™ ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Devaki Surasi discussing combination sequencing for PSMA-based therapy in advanced disease. Dr. Surasi started with ...

The approval of ¹⁷⁷Lu-PSMA-617 for adult patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) previously treated with androgen receptor pathway inhibitors and ...